A new NIH-funded trial at UTHealth Houston investigates why weight regain after stopping GLP-1 medications varies by exploring genetics and metabolic memory.
On October 2, 2026, UTHealth Houston announced that its researchers received a major National Institutes of Health grant. The NIH awarded a grant of 4 million dollars over five years to support this specific project. The funding will allow researchers to investigate why some people regain weight after stopping GLP-1 medications while others retain more of their weight loss. This variation in post-treatment outcomes is one of the most pressing questions in modern metabolic health.
The planned study is a randomized and blinded trial that will enroll 100 participants with obesity. These individuals will be recruited directly from the Border Health Research Cohort. The UTHealth Houston announcement describes this research center as focused on risk factors for obesity, diabetes, and related complications. The cohort maintains a specific focus on Americans of Mexican descent living in the Lower Rio Grande Valley.
UTHealth Houston identifies Absalon Gutierrez, MD, as the principal investigator for this comprehensive project. Joseph B. McCormick, MD, will serve alongside him as the co-principal investigator. The project is being conducted in close collaboration with Vanderbilt University and the Border Health Research Center at UTHealth Houston.
The trial follows a very specific structural design to isolate the effects of medication withdrawal. All participants will receive semaglutide for six consecutive months. Afterward, half of the group will be randomly selected to stop the medication. The other half will continue their GLP-1 therapy, which allows researchers to compare the two distinct paths.
The biological pathways behind these differing outcomes are not yet known. To uncover answers, researchers plan to examine genetic markers related to insulin metabolism, energy expenditure, appetite hormones, and body composition. Insulin metabolism refers to how the body manages blood sugar and stores energy for later use. When treatment stops, changes in this system can alter how efficiently calories are processed.
Energy expenditure is another vital piece of the metabolic puzzle. It represents the total volume of calories a person burns through resting functions and daily movement. Appetite hormones act as chemical messengers that regulate feelings of hunger and satiety. When patients discontinue treatment, shifts in these hormones can dramatically increase appetite and drive intense food consumption.
Body composition changes also play a significant role in long-term metabolic health. Losing muscle mass during active weight loss can lower resting energy expenditure over time. The research team wants to determine if certain genetic profiles make patients more vulnerable to these compounding biological shifts. Gutierrez stated that the research could help identify people who may be genetically predisposed to regain weight after stopping GLP-1 receptor agonist medications.
McCormick characterized post-discontinuation regain as a significant clinical problem that requires detailed biological investigation. He noted that the trial will investigate why outcomes differ so widely among patients. This includes studying the possibility of a metabolic memory related to the initial treatment phase. A metabolic memory suggests that the initial period on semaglutide might permanently alter how the body responds to future weight changes.
Mainstream discussions about weight regain after stopping GLP-1 medications are often saturated with extreme claims. Some media outlets suggest that everyone will inevitably regain all their weight the moment they stop treatment. Others falsely claim that simple genetic tests can already predict a patient's exact long-term outcome. Both of these extreme narratives distort the current reality of metabolic science.
Many fitness publications still frame weight regain as a simple failure of personal dedication. In reality, weight change is driven by complex interactions between appetite, treatment history, environment, and genetics. The NIH-funded project is prospective research, meaning it describes planned aims rather than completed findings. The study has not yet reported any results, so its proposed genetic markers remain open research questions.
Concepts like metabolic memory and predictive genetic markers are not yet proven explanations or available clinical tests. McCormick said the work could identify potential drug targets and predictive biomarkers in the future. However, these are stated research possibilities and not established results of the current study. We do not yet have the tools to tell individual patients exactly how their bodies will react.
The grant announcement specifically describes a study of 100 people from a particular regional cohort. The sources do not establish that any eventual findings will apply equally to all diverse populations. Furthermore, the sources do not provide an individualized medication-stopping plan for current patients. Readers should avoid treating this research announcement as an established tapering strategy or a confirmed method to prevent regain.
While the biological mechanisms are still being investigated, past trials show what happens across large populations. The STEP 1 extension trial provides a prior example of average weight regain after semaglutide withdrawal. The summary of this extension reported that participants lost an average of 17.3 percent of their body weight during 68 weeks of active semaglutide treatment. This initial phase represented a profound metabolic shift for the participants involved.
After the treatment was withdrawn, participants experienced a significant shift in body weight. They regained an average of 11.6 percentage points in the period following the medication stoppage. This dynamic left the study group with a net weight loss of 5.6 percent at the final follow-up evaluation. These figures highlight a clear biological weight rebound trend across the broader participant group.
However, it is crucial to remember that these numbers represent an average from a specific study context. The STEP 1 extension figure should not be presented as a guaranteed forecast for every person who stops semaglutide. Group averages blend together the results of individuals who maintained their weight loss and those who regained completely. The reported group averages do not establish why particular individuals regain more or less weight.
This sheer unpredictability is exactly why the planned UTHealth Houston study is so important for medical science. The new trial's randomized continuation-versus-discontinuation design is intended to investigate mechanisms that the cited STEP 1 summary does not answer. By measuring actual biological changes over time, researchers hope to replace these broad averages with precise metabolic data.
The next five years will provide essential data regarding metabolic changes after ending semaglutide therapy. Future research must determine whether these specific genetic markers can truly predict individual patient outcomes across larger populations. Until scientists can isolate these variables, weight change after stopping treatment remains a complex process driven by genetics, appetite, and environment. Clearer predictive biomarkers are required before individualized discontinuation protocols can become standard medical practice.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
